BioSpace News Archive

Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”) today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou (PRIG) announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) TC Cream to launch a U.S.-based multicenter Phase III clinical study to treat patients with psoriasis vulgaris, following a previously completed Phase IIb trial (NCT03372811).

The Insight Partners published latest research report on “Molecular Biology Enzymes, Kits, and Reagents Market Growth Report, Size, Share, Trends & Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, and End User

Theranica announced the results of a recent study published in the Journal of Medical Economics, showing that Nerivio®, a novel Remote Electrical Neuromodulation (REN) wearable, provides significant cost savings in addition to clinical benefits when used as a preventive migraine treatment.

Cantex Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 11,648,235, titled “Treatment of Glioblastoma,” with claims to a method of treating glioblastoma with azeliragon.

Eluminex Biosciences (Eluminex) announced that its clinical pivotal study (CLARITY) evaluating a novel biosynthetic corneal implant (EB-301) currently being conducted in China was recognized for its groundbreaking work at two recent international ophthalmology meetings held in the United States.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, recognized the progress and impact of genomic technologies on pathogen preparedness and response.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced plans to accelerate the expansion of the Newton™ Knee to the Asia-Pacific region.

Pfizer Inc. announced the pricing of a debt offering consisting of eight tranches of notes.

Innovent Biologics, Inc. today announces that about 30 accepted abstracts of clinical data from multiple trials in relation to TYVYT® (sintilimab injection), olverembatinib (BCR-ABL TKI), IBI326 (equecabtagene autoleucel), IBI376 (parsaclisib), IBI110 (anti-LAG-3 monoclonal antibody), IBI939 (anti-TIGIT monoclonal antibody) and IBI351 (KRASG12C inhibitor) will be presented at the upcoming international medical conferences.